Pharma BD Deal Intelligence
KKR and Integer Holdings announced a definitive agreement on August 3, 2026 under which an affiliate of KKR-managed investment funds will acquire all outstanding shares of Integer in an all-cash take-private valued at an enterprise value of approximately $5.7 billion. Integer stockholders will receive $127.00 per share, a premium of approximately 51.8% to the April 29, 2026 close preceding Integer's strategic-review announcement and 28.8% to the 30-day VWAP as of July 31, 2026. Integer's board unanimously approved the transaction, which followed a board-led strategic review. Integer will become privately held and delist from the NYSE; closing is expected by year-end 2026 subject to customary conditions.
← Browse all deals · How we score deals
More: 2026 deals